摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil | 306305-17-9

中文名称
——
中文别名
——
英文名称
1-(4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil
英文别名
4'-C-triethylsilylethynyl-5-fluorouridine;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-5-(2-triethylsilylethynyl)oxolan-2-yl]-5-fluoropyrimidine-2,4-dione
1-(4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil化学式
CAS
306305-17-9
化学式
C17H25FN2O6Si
mdl
——
分子量
400.479
InChiKey
KJAPKHXBGOWOEX-IARIHHJXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.35±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.29
  • 重原子数:
    27
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    119
  • 氢给体数:
    4
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil吡啶偶氮二异丁腈三正丁基氢锡4-氯苯基二氯磷酸酯 作用下, 以 甲苯乙腈 为溶剂, 反应 4.0h, 生成 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-(5-fluoro-2-oxo-4-[1,2,4]triazol-1-yl-2H-pyrimidin-1-yl)-2-triethylsilanylethynyl-tetrahydro-furan-3-yl ester
    参考文献:
    名称:
    [EN] 4'-ALKYNE-2'-DEOXYCYTIDINE-BASED COMPOUNDS AND ANTI-CANCER USES THEREOF
    [FR] COMPOSÉS À BASE DE 4'-ALCYNE-2'-DÉSOXYCYTIDINE ET LEURS UTILISATIONS ANTICANCÉREUSES
    摘要:
    This invention relates, in part, to 4'-alkyne-2'-deoxycytidine-based compounds and derivatives and pharmaceutical compositions thereof for preventing or treating cancers.
    公开号:
    WO2024015916A2
  • 作为产物:
    描述:
    1-(2-O-acetyl-3,5-di-O-benzyl-4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil 在 甲醇三氯化硼三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 50.0h, 生成 1-(4-C-triethylsilylethynyl-β-D-ribo-pentofuranosyl)-5-fluorouracil
    参考文献:
    名称:
    Syntheses of 4-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity
    摘要:
    4'-C-Ethynyl-beta -D-arabino- and 4'-C-ethynyl-2'-deoxy-beta -D-ribo-pentofuranosylpyrine and -purine nucleosides were synthesized and evaluated for their in vitro anti-HIV activity. The key intermediate, 4-C-ethynyl- or 4-C-triethylsilylethynyl-D-ribo-pentofuranose, was prepared from D-glucose and glycosidated with various pyrimidine or purine bases. The arabino pyrimidine derivatives were prepared from the corresponding ribo derivatives via O-2,2'-anhydro nucleosides. The 2'-deoxy-ribo derivatives were synthesized by radical reduction of 2'-bromo or 2'- phenoxythiocarbonyloxy nucleosides. Among these 4'-C-ethynyl nucleosides, seven analogues proved to be potent against HIV-1 in vitro with EC50 values ranging from 0.0003 to 0.03 muM. These compounds also exerted activity against clinical and multi-dideoxy-nucleoside-resistant HIV-1 strains with comparable EC50 values. Three such 4'-C-ethynyl-2'-deoxypurine analogues including 4'-C-ethynyl-2'-deoxyadenosine and 4'-C-ethynyl-2,6-diamino-2'-deoxy-purine were less cytotoxic [selectivity indices (SIs): 975-2733] than three 4'-C-ethynyl-2-deoxycytidine analogues (SIs: 63-363). 4'-C-Ethynyl-5-fluoro-2'-deoxycytidine was least toxic (SI: >3333) and potent against all HIV strains tested.
    DOI:
    10.1021/jm000209n
点击查看最新优质反应信息

文献信息

  • 4′-C-ethynyl pyrimidine nucleoside compounds and pharmaceutical compositions
    申请人:Yamasa Corporation
    公开号:US06291670B1
    公开(公告)日:2001-09-18
    The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.
    该发明提供了由公式[I]表示的4'-C-乙炔嘧啶核苷(除了4'-C-乙炔胸腺嘧啶):其中B代表从嘧啶及其衍生物组成的基;X代表氢原子或羟基;R代表氢原子或磷酸酯基团;以及含有任一化合物和药学上可接受的载体的药物组合物。最好,该组合物用作抗HIV药剂或治疗艾滋病的药物。
  • Syntheses of 4<i>‘</i><i>-</i><i>C</i>-Ethynyl-β-<scp>d</scp>-<i>arabino- </i>and 4‘-<i>C-</i>Ethynyl-2<i>‘</i>-deoxy-β-<scp>d</scp>-<i>ribo-</i>pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity
    作者:Hiroshi Ohrui、Satoru Kohgo、Kenji Kitano、Shinji Sakata、Eiichi Kodama、Kazuhisa Yoshimura、Masao Matsuoka、Shiro Shigeta、Hiroaki Mitsuya
    DOI:10.1021/jm000209n
    日期:2000.11.1
    4'-C-Ethynyl-beta -D-arabino- and 4'-C-ethynyl-2'-deoxy-beta -D-ribo-pentofuranosylpyrine and -purine nucleosides were synthesized and evaluated for their in vitro anti-HIV activity. The key intermediate, 4-C-ethynyl- or 4-C-triethylsilylethynyl-D-ribo-pentofuranose, was prepared from D-glucose and glycosidated with various pyrimidine or purine bases. The arabino pyrimidine derivatives were prepared from the corresponding ribo derivatives via O-2,2'-anhydro nucleosides. The 2'-deoxy-ribo derivatives were synthesized by radical reduction of 2'-bromo or 2'- phenoxythiocarbonyloxy nucleosides. Among these 4'-C-ethynyl nucleosides, seven analogues proved to be potent against HIV-1 in vitro with EC50 values ranging from 0.0003 to 0.03 muM. These compounds also exerted activity against clinical and multi-dideoxy-nucleoside-resistant HIV-1 strains with comparable EC50 values. Three such 4'-C-ethynyl-2'-deoxypurine analogues including 4'-C-ethynyl-2'-deoxyadenosine and 4'-C-ethynyl-2,6-diamino-2'-deoxy-purine were less cytotoxic [selectivity indices (SIs): 975-2733] than three 4'-C-ethynyl-2-deoxycytidine analogues (SIs: 63-363). 4'-C-Ethynyl-5-fluoro-2'-deoxycytidine was least toxic (SI: >3333) and potent against all HIV strains tested.
  • [EN] 4'-ALKYNE-2'-DEOXYCYTIDINE-BASED COMPOUNDS AND ANTI-CANCER USES THEREOF<br/>[FR] COMPOSÉS À BASE DE 4'-ALCYNE-2'-DÉSOXYCYTIDINE ET LEURS UTILISATIONS ANTICANCÉREUSES
    申请人:[en]THOMAS JEFFERSON UNIVERSITY
    公开号:WO2024015916A2
    公开(公告)日:2024-01-18
    This invention relates, in part, to 4'-alkyne-2'-deoxycytidine-based compounds and derivatives and pharmaceutical compositions thereof for preventing or treating cancers.
查看更多